(Q37546125)

20 August 2017

1 reference

title

Drugs in development for the treatment of schizophrenia (English)

1 reference

20 August 2017

0 references

Robin Emsley

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Investigational Drugs

20 August 2017

published in

1 reference

20 August 2017

volume

18

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

1103-1118

1 reference

Size of burden of schizophrenia and psychotic disorders

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

The evolution of drug development in schizophrenia: past issues and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Refractory schizophrenia and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Definitions of response and remission in schizophrenia: recommendations for their use and their presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Negative symptoms of schizophrenia: a problem that will not go away

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

New paradigms for treatment development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Metabolic side effects of antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Symptom domains of schizophrenia: the role of atypical antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Schizophrenia endophenotypes as treatment targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Dopamine hypothesis of schizophrenia: making sense of it all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Better pharmacotherapy for schizophrenia: what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

The pipeline and future of drug development in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Alterations of dopamine and serotonin transmission in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Glutamate as a therapeutic target in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Direct and indirect modulation of the N-methyl D-aspartate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Genes for schizophrenia? Recent findings and their pathophysiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

The possible involvement of metabotropic glutamate receptors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Role of glutamate in schizophrenia: integrating excitatory avenues of research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Guanfacine treatment of cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Iloperidone binding to human and rat dopamine and 5-HT receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Remission in schizophrenia: proposed criteria and rationale for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Much ado about small differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903066756

10.1517/13543780903066756

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference